查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1956822

先进生物製品製造市场分析及预测（至2035年）：类型、产品类型、服务、技术、应用、最终用户、製程、组件及实施方案

Advanced Biologics Manufacturing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Component, Deployment
出版日期: | 出版商: Global Insight Services | 英文 330 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到2034年，先进生物製药生产市场规模将从2024年的5,630亿美元成长至1,5,459亿美元，复合年增长率约为12.2%。先进生物製品生产市场涵盖单株抗体、疫苗和细胞疗法等复杂生物製品的生产。该市场的发展动力源于生物技术的进步，并需要最先进的设施和技术来实现精准化和扩充性。主要趋势包括采用一次性系统、自动化以及整合连续生产流程。随着个人化医疗和生物製药创新不断涌现，对产能和监管合规性的要求也随之提高，市场可望持续成长。

受个人化医疗和创新治疗方法需求不断增长的推动，先进生物製剂生产市场正经历强劲成长。细胞疗法细分市场是成长最快的次细分市场，这主要得益于CAR-T疗法和干细胞研究的进展。基因疗法紧随其后，对CRISPR等基因编辑技术的巨额投资有助于提高治疗效果。生物製程设备和试剂是支持高品质生物製剂生产的关键组成部分，有助于提高规模化生产效率。一次性技术正日益普及，为生产过程提供柔软性和成本效益。随着製药公司寻求优化资源并专注于核心竞争力，契约製造组织（CMO）市场持续扩张。连续生物加工已成为一种变革性方法，能够提高产量并缩短生产时间。随着法规结构的不断完善以适应这些创新，预计未来市场将进一步扩张，重点关注永续和高效的生产方法，从而推动市场成长。

市场区隔
类型 重组蛋白、单株抗体、细胞疗法、基因疗法、疫苗、抗体药物复合体、生物相似药
产品 生物反应器、离心机、层析法系统、过滤系统、一次性系统、细胞培养基、缓衝液和试剂
服务 契约製造、製程开发、分析测试、法规遵循、品质保证、供应链管理
科技 上游工程、下游、连续製造、一次性技术、自动化、製程分析技术
应用领域 肿瘤科、心血管疾病科、神经系统疾病科、感染疾病、自体免疫疾病科、代谢性疾病科
最终用户 製药公司、生技公司、研究机构、受託研究机构、学术机构
流程 发酵、纯化、配製、填充、冷冻干燥、包装
成分 原料、耗材、设备、软体
部署表 内部开发、外包、混合模式

先进生物製剂生产市场正经历动态变化，其特点是策略性定价模式的运用和新产品推出数量的激增。主要企业正利用创新技术来获取市场份额，并专注于成本效益和品质提升。市场正见证着个人化医疗的发展趋势，这推动了对先进生物製剂的需求。新型疗法的推出正在重塑竞争格局，各公司正大力投资研发以保持竞争优势。竞争日趋激烈，主要企业相互参照，以优化生产流程并加速产品上市速度。监管的影响，尤其是在北美和欧洲，至关重要，它塑造着营运标准和合规要求。强大的生物製剂产品线是该市场的标誌，这得益于生物技术的进步和对永续生产实践日益增长的关注。监管机构越来越重视透明度和安全性，影响市场动态。技术创新和策略联盟为行业成长提供了支撑。

主要趋势和驱动因素：

受慢性病发病率上升和个人化医疗需求日益增长的推动，先进生物製药生产市场正经历强劲增长。关键趋势包括细胞和基因治疗生产技术的进步，这些技术提高了生产效率并降低了成本。监管机构也在简化核准流程，鼓励创新并加速新生物製药产品的市场准入。生物製药公司正大力投资研发新型生物製药，进一步推动市场扩张。值得注意的是，将生产流程外包给专业的合约研发生产机构（CDMO）的趋势日益明显，这使得企业能够专注于自身核心竞争力，同时利用CDMO的专业知识和基础设施。此外，一次性技术的日益普及提高了柔软性并降低了污染风险。人工智慧（AI）和机器学习在生物製药生产中的应用正在优化生产流程并提高产品品质。因此，预计该市场将迎来显着成长，为那些愿意创新并适应这些发展趋势的公司创造众多机会。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 重组蛋白
    • 单株抗体
    • 细胞疗法
    • 基因治疗
    • 疫苗
    • 抗体药物复合体
    • 生物相似药
  • 市场规模及预测：依产品划分
    • 生物反应器
    • 离心机
    • 层析法系统
    • 过滤系统
    • 免洗系统
    • 细胞培养基
    • 缓衝液和试剂
  • 市场规模及预测：依服务划分
    • 契约製造
    • 製程开发
    • 分析测试
    • 监理合规
    • 品质保证
    • 供应链管理
  • 市场规模及预测：依技术划分
    • 上游工程
    • 下游工艺
    • 连续製造
    • 免洗技术
    • 自动化
    • 过程分析技术
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 心血管疾病
    • 神经系统疾病
    • 感染疾病
    • 自体免疫疾病
    • 代谢性疾病
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 生技公司
    • 研究所
    • 合约研究机构
    • 学术机构
  • 市场规模及预测：依製程划分
    • 发酵
    • 纯化
    • 配方
    • 填充
    • 冷冻干燥
    • 包装
  • 市场规模及预测：依组件划分
    • 原料
    • 消耗品
    • 装置
    • 软体
  • 市场规模及预测：依发展状况
    • 内部
    • 外包
    • 杂交种

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Wu Xi Biologics
  • Samsung Biologics
  • Lonza
  • Boehringer Ingelheim Bio Xcellence
  • Catalent
  • Fujifilm Diosynth Biotechnologies
  • AGC Biologics
  • Cytiva
  • Thermo Fisher Scientific
  • Sartorius
  • Bio NTech
  • Biocon
  • Abzena
  • Rentschler Biopharma
  • Wacker Biotech
  • KBI Biopharma
  • Just Evotec Biologics
  • Ab Cellera Biologics
  • Cognate Bio Services
  • Eurofins CDMO

第九章：关于我们

简介目录
Product Code: GIS32964

Advanced Biologics Manufacturing Market is anticipated to expand from $563.0 billion in 2024 to $1,545.9 billion by 2034, growing at a CAGR of approximately 12.2%. The Advanced Biologics Manufacturing Market encompasses the production of complex biological products, including monoclonal antibodies, vaccines, and cell therapies. This market is driven by advancements in biotechnology, necessitating cutting-edge facilities and technologies for precision and scalability. Key trends include the integration of single-use systems, automation, and continuous manufacturing processes. The market is poised for growth as personalized medicine and biopharmaceutical innovations expand, requiring enhanced production capabilities and regulatory compliance.

The Advanced Biologics Manufacturing Market is experiencing robust growth, fueled by the increasing demand for personalized medicines and innovative therapies. The cell therapy segment is the top-performing sub-segment, driven by advancements in CAR-T therapies and stem cell research. Gene therapy follows closely, with significant investments in CRISPR and other gene-editing technologies enhancing therapeutic efficacy. Bioprocessing equipment and reagents are critical, supporting the production of high-quality biologics with improved scalability and efficiency. Single-use technologies are gaining prominence, offering flexibility and cost-effectiveness in manufacturing processes. The contract manufacturing organizations (CMOs) segment is expanding, as pharmaceutical companies seek to optimize resources and focus on core competencies. Continuous bioprocessing is emerging as a transformative approach, improving yields and reducing production timelines. As regulatory frameworks evolve to accommodate these innovations, the market is poised for further expansion, with a focus on sustainable and efficient manufacturing practices driving future growth.

Market Segmentation
TypeRecombinant Proteins, Monoclonal Antibodies, Cell Therapy, Gene Therapy, Vaccines, Antibody Drug Conjugates, Biosimilars
ProductBioreactors, Centrifuges, Chromatography Systems, Filtration Systems, Single-use Systems, Cell Culture Media, Buffers and Reagents
ServicesContract Manufacturing, Process Development, Analytical Testing, Regulatory Compliance, Quality Assurance, Supply Chain Management
TechnologyUpstream Processing, Downstream Processing, Continuous Manufacturing, Single-use Technology, Automation, Process Analytical Technology
ApplicationOncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Autoimmune Diseases, Metabolic Disorders
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Research Organizations, Academic Institutions
ProcessFermentation, Purification, Formulation, Filling, Lyophilization, Packaging
ComponentRaw Materials, Consumables, Equipment, Software
DeploymentIn-house, Outsourced, Hybrid

The Advanced Biologics Manufacturing Market is experiencing a dynamic shift, marked by strategic pricing models and a surge of new product launches. Key industry players are leveraging innovative technologies to capture market share, focusing on cost-efficiency and quality enhancement. The market is seeing a trend towards personalized medicine, driving demand for advanced biologics. The introduction of novel therapeutics is reshaping competitive landscapes, with companies investing heavily in R&D to maintain a competitive edge. Competition is fierce, with leading firms benchmarking against each other to optimize production processes and reduce time-to-market. Regulatory influences, particularly in North America and Europe, are pivotal, shaping operational standards and compliance requirements. The market is characterized by a robust pipeline of biologics, driven by advancements in biotechnology and a growing emphasis on sustainable manufacturing practices. Regulatory bodies are increasingly focusing on transparency and safety, impacting market dynamics. The industry's growth is underpinned by technological innovations and strategic alliances.

Geographical Overview:

The Advanced Biologics Manufacturing Market is witnessing dynamic growth across various regions, each with unique opportunities. North America remains a leader, driven by robust research and development initiatives and substantial investments in biotechnology. The presence of major pharmaceutical companies and advanced healthcare infrastructure further propels the market. Europe follows closely, with its strong regulatory framework and emphasis on biopharmaceutical innovation. The region's commitment to sustainable and cutting-edge biologics manufacturing enhances its market position. In Asia Pacific, the market is expanding rapidly, fueled by increasing demand for biologics and government support for biotechnology. Countries like China and India are emerging as significant players due to their growing investment in healthcare infrastructure and research capabilities. Latin America and the Middle East & Africa are also gaining traction. These regions are recognizing the potential of advanced biologics manufacturing to address unmet medical needs and drive economic growth, signaling new growth pockets.

Global tariffs and geopolitical tensions are significantly influencing the Advanced Biologics Manufacturing Market, particularly in East Asia. Japan and South Korea, with their robust technological infrastructure, are enhancing domestic biologics capabilities to mitigate reliance on foreign imports amid trade uncertainties. China is accelerating its strategic pivot towards self-sufficiency, investing heavily in biomanufacturing infrastructure to counteract export restrictions. Taiwan, while a critical player in biologics innovation, faces geopolitical vulnerabilities due to its proximity to China. The parent market is witnessing robust growth driven by rising demand for biologics, yet supply chain disruptions and tariff-induced cost pressures persist. By 2035, the market is expected to expand significantly, contingent upon regional collaborations and resilient supply networks. Middle East conflicts may exacerbate global energy costs, indirectly affecting manufacturing expenses and supply chain logistics.

Key Trends and Drivers:

The Advanced Biologics Manufacturing Market is experiencing robust growth, fueled by the increasing prevalence of chronic diseases and the rising demand for personalized medicine. Key trends include advancements in cell and gene therapy manufacturing technologies, which are enhancing production efficiencies and reducing costs. Regulatory agencies are also streamlining approval processes, encouraging innovation and expediting the market entry of new biologics. Biopharmaceutical companies are investing heavily in research and development to create novel biologic products, further driving market expansion. The growing trend of outsourcing manufacturing processes to specialized contract development and manufacturing organizations (CDMOs) is also noteworthy. This allows companies to focus on core competencies while leveraging the expertise and infrastructure of CDMOs. Moreover, the adoption of single-use technologies is gaining traction, offering flexibility and reducing contamination risks. The integration of artificial intelligence and machine learning in biologics manufacturing is optimizing production processes and enhancing product quality. As a result, the market is poised for substantial growth, with numerous opportunities for companies that innovate and adapt to these evolving trends.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Deployment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Recombinant Proteins
    • 4.1.2 Monoclonal Antibodies
    • 4.1.3 Cell Therapy
    • 4.1.4 Gene Therapy
    • 4.1.5 Vaccines
    • 4.1.6 Antibody Drug Conjugates
    • 4.1.7 Biosimilars
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Bioreactors
    • 4.2.2 Centrifuges
    • 4.2.3 Chromatography Systems
    • 4.2.4 Filtration Systems
    • 4.2.5 Single-use Systems
    • 4.2.6 Cell Culture Media
    • 4.2.7 Buffers and Reagents
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Contract Manufacturing
    • 4.3.2 Process Development
    • 4.3.3 Analytical Testing
    • 4.3.4 Regulatory Compliance
    • 4.3.5 Quality Assurance
    • 4.3.6 Supply Chain Management
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Upstream Processing
    • 4.4.2 Downstream Processing
    • 4.4.3 Continuous Manufacturing
    • 4.4.4 Single-use Technology
    • 4.4.5 Automation
    • 4.4.6 Process Analytical Technology
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiovascular Diseases
    • 4.5.3 Neurological Disorders
    • 4.5.4 Infectious Diseases
    • 4.5.5 Autoimmune Diseases
    • 4.5.6 Metabolic Disorders
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Contract Research Organizations
    • 4.6.5 Academic Institutions
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Fermentation
    • 4.7.2 Purification
    • 4.7.3 Formulation
    • 4.7.4 Filling
    • 4.7.5 Lyophilization
    • 4.7.6 Packaging
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Raw Materials
    • 4.8.2 Consumables
    • 4.8.3 Equipment
    • 4.8.4 Software
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 In-house
    • 4.9.2 Outsourced
    • 4.9.3 Hybrid

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Component
      • 5.2.1.9 Deployment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Component
      • 5.2.2.9 Deployment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Component
      • 5.2.3.9 Deployment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Component
      • 5.3.1.9 Deployment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Component
      • 5.3.2.9 Deployment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Component
      • 5.3.3.9 Deployment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Component
      • 5.4.1.9 Deployment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Component
      • 5.4.2.9 Deployment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Component
      • 5.4.3.9 Deployment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Component
      • 5.4.4.9 Deployment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Component
      • 5.4.5.9 Deployment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Component
      • 5.4.6.9 Deployment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Component
      • 5.4.7.9 Deployment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Component
      • 5.5.1.9 Deployment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Component
      • 5.5.2.9 Deployment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Component
      • 5.5.3.9 Deployment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Component
      • 5.5.4.9 Deployment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Component
      • 5.5.5.9 Deployment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Component
      • 5.5.6.9 Deployment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Component
      • 5.6.1.9 Deployment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Component
      • 5.6.2.9 Deployment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Component
      • 5.6.3.9 Deployment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Component
      • 5.6.4.9 Deployment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Component
      • 5.6.5.9 Deployment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Wu Xi Biologics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Samsung Biologics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Lonza
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Boehringer Ingelheim Bio Xcellence
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Catalent
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Fujifilm Diosynth Biotechnologies
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 AGC Biologics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cytiva
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Thermo Fisher Scientific
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Sartorius
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Bio NTech
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Biocon
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Abzena
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Rentschler Biopharma
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Wacker Biotech
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 KBI Biopharma
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Just Evotec Biologics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Ab Cellera Biologics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Cognate Bio Services
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Eurofins CDMO
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us